Therefore, combining an anti-angiogenic treatment such as bevacizumab (VEGF inhibitor) with vaccine seems a valid strategy to enhance the anti-cancer T cells (triggered by the vaccine) homing to tumor. This evidence concerns the gene VEGFA and cancer.